![]() His emphasis on professional organisational design, precise execution and operational efficiencies has built a strong and globally competitive generic business platform in Torrent Pharma. Under his leadership, Torrent Pharma took several strategic initiatives, including forays into new therapies and geographies, large investments in product development infrastructure and capabilities, building state-of-the-art manufacturing facilities and acquisitions, thus establishing Torrent as one of India’s fast growing and well respected Pharma majors. ![]() It has also set up power transmission infrastructure for catering to its distribution business. ![]() It distributes power to 24.5 lacs customers in Ahmedabad, Gandhinagar and Surat in Gujarat as a “distribution licensee” and to 6.68 lacs customers in the cities of Agra and Bhiwandi as a “distribution franchisee”. The company has a generation capacity of 3600 MW. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API Plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business and its Sikkim Plant in 2017 strengthened Torrent Pharma's position.Īlongside, Torrent Power today has a strong foothold in generation, distribution and transmission segments. Torrent Pharma’s global operations are spread across 40 countries with wholly owned subsidiaries in most major markets. Torrent Pharma today has a strong presence in various therapeutic segments with eight world-class operational manufacturing plants and a state-of-the-art research centre. Mehta, Torrent Group has since grown into a leading business group. Mehta took over as the Chairman of the Torrent Group in 1998 after the demise of his father, Mr. As a result of his efforts, a 655 MW dual fuel combined cycle power project was commissioned within stipulated cost and time. Over the years, he planned strategies and built resources with an aim of making Torrent Power a leader in this sector. This was followed by the acquisition of The Ahmedabad Electricity Company and The Surat Electricity Company in the early 90’s now part of Torrent Power Ltd. Mehta was quick to foresee the emerging opportunities in the power sector and he lead Torrent’s foray into this sector by the acquisition of the ailing Mahendra Cables in late 80’s, now known as Torrent Cables Ltd. In recognition of its superior performance, Torrent Pharma earned the President’s award for highest pharmaceuticals exports of Rs. He was instrumental in the commissioning of its first manufacturing facility at Ahmedabad and bagging the first export order to Russia. He brought in great dynamism and large business acumen into the Group resulting into the initial success of Torrent Pharma, the flagship company of the Torrent Group. Mehta joined his father in managing the affairs of Torrent Pharma and began learning the nuances of business and management under his watchful eyes. ![]() Sudhir Mehta formally joined the family business in the early 70s.Īfter completing his education, Mr. 21000 Crore Torrent Group, is the driving force behind its strong presence in Pharma and Power sectors. Shares of Torrent Pharmaceuticals Ltd closed at Rs 1,666.15 per scrip on BSE, up 3.26 per cent from the previous close.Mr. ![]() The company, however, did not share any details about the concerns raised by the US regulator in its warning letter. The company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities, it added. “We will be engaging with the agency and are fully committed in resolving this issue at the earliest,” Torrent Pharma said. The company does not believe that the warning letter will have an impact of disruption of supplies or the existing revenues from operations of this facility, it added. This action by the United States Food and Drug Administration (USFDA) follows earlier intimation received from the regulator in August 2019, wherein the agency had classified its inspection as “Official Action Indicated” (OAI), Torrent Pharma said in a regulatory filing. Drug firm Torrent Pharmaceuticals on Wednesday said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |